Dr. Ervinna Pang, Phd, Cva Email and Phone Number
Dr. Ervinna Pang, Phd, Cva work email
- Valid
Dr. Ervinna Pang, Phd, Cva personal email
Dr. Ervinna Pang, Phd, Cva is a Adjunct Asst Prof at Nanyang Technological University Singapore. They is proficient in French, German, English and Bahasa Indonesia/Malay.
-
Adjunct Asst ProfNanyang Technological University SingaporeSingapore
-
Adjunct Asst ProfNanyang Technological University Singapore May 2024 - PresentSingapore -
Chief Business OfficerBiocheetah Pte Ltd May 2024 - Present -
AdvisorBiocheetah Pte Ltd Jun 2019 - Jul 2024
-
Group Director, Business Development & Investor RelationsBiocheetah Pte Ltd Jun 2018 - Jun 2019BioCheetah is a Medtech (in vitro diagnostics/IVD) company that develops a proprietary set of novel biomarkers and detection antibodies for diagnostic applications. Its most advanced non-invasive, protein-based ELISA test kit, for diagnosis and monitoring of bladder cancer is available as a lab-developed test (LDT) and will be launched soon as IVD for clinical utility. Other products in development include Point-of-Care Test (POCT) kits.BioCheetah also runs an ISO13485:2016-certified facility in Singapore.
-
Director, Co11AbNtuitive Oct 2021 - May 2024Singaporeco11ab is Singapore's first BioMedtech incubator embedded within a health city (HealthCity Novena). It is a tripartite alliance between Nanyang Technological University, Singapore (NTU), Agency for Science, Technology and Research, Singapore (A*STAR) and National Healthcare Group, Singapore (NHG). Its mission is to nurture and support development of biomedical technologies via technology translations, spin-offs creation and incubation. -
AdvisorBiosyngen Jun 2019 - Sep 2021Singapore And China -
Group Director, Business Development & Investor RelationsBiosyngen Jun 2018 - Jun 2019Singapore And ChinaBioSyngen is a clinical-stage cell therapy Biotech company, developing multiple T-cell immunotherapies to address unmet needs in oncology.BioSyngen operates GMP-compliance facilities for cell therapy in Singapore and China.
-
CeoImmunoa Pte. Ltd. May 2019 - Sep 2021SingaporeImmuNOA is a genetic engineering (antisense therapy) Biotech company. We rationally design and test our proprietary library of antisense oligonucleotides to improve immunotherapy efficacy in the treatment of multiple pathologies.Multiple proprietary antisense oligonucleotides against different checkpoint inhibitors have been deployed to transiently modify immune cells, such as T cells, for the development of next-generation T cell therapies. -
Board Of DirectorsImmunoa Pte. Ltd. May 2019 - Sep 2021Singapore
-
Board ObserverLion Tcr May 2019 - Aug 2019Singapore And China -
Group Director, Business Development & Investor RelationsLion Tcr Jun 2018 - Aug 2019Singapore And ChinaLion TCR is a clinical-stage TCR-T cell therapy Biotech company that discovers, develops, and commercializes first-in-class and best-in-class TCR-T cell therapy against viral infections and related cancers.Lion TCR operates GMP-compliance facilities for cell therapy.
-
Group Director, Business Development & Investor RelationsScg Cell Therapy Jun 2018 - Jun 2019Singapore And ChinaSCG Cell Therapy is a clinical-stage Biotech company focusing on the development of novel immunotherapies for patients with pathogenic infections and associated cancers. SCG Cell Therapy operates GMP-compliance facilities for cell therapy. -
Associate Director, External Innovation & Business DevelopmentBoehringer Ingelheim Oct 2017 - May 2018ChinaPart of global Boehringer Ingelheim (BI)’s Research Beyond Borders (RBB). As “radar” for the next big wave of innovation, RBB explores emerging science and technologies both within and beyond BI’s core therapeutic areas. New frontiers in science involved were Gene therapy (Adeno-Associated Virus/AAV) and Regenerative medicine. Therapeutic areas involved were Cancer Immunology & Immune-modulation, Cancer, Central Nervous System, Cardio Metabolic Diseases, and Respiratory.Also, part of BI's China Business Development Unit. -
HeadA*Star - Agency For Science, Technology And Research Feb 2016 - Sep 2017SingaporeInnovation and Enterprise unit of A*STAR (formerly known as Exploit Technologies Pte Ltd or Accelerate Technologies Pte Ltd).Division PharmBiotech: Business Development & Licensing. -
Scientific ManagerBayer Healthcare Oct 2014 - Jan 2016Global Therapeutic Research Groups (Oncology)- GermanyCancer Immunotherapy -
Alliance ManagementBayer Healthcare Jul 2013 - Sep 2014Global External Innovation & Alliances- ApacExternal partnerships (from target discovery to Ph. I clinical trial)
-
Phd FellowMax Planck Institute For Infection Biology Feb 2010 - Jun 2013GermanyResearch disciplines: Molecular Biology, Oncology, Infection Biology, Immunology.Topics: *The Helicobacter pylori virulence effector CagA abrogates Human β-Defensin 3 expression via inactivation of EGFR signaling (published in Cell Host & Microbe, 2012).*Helicobacter pylori depletes cholesterol in gastric glands to prevent Interferon Gamma signaling and escape the inflammatory response (published in Gastroenterology, 2017). -
Senior ResearcherInstitute Of Medical Biology, A*Star, Singapore Mar 2009 - Jan 2010SingaporeSingapore OncoGenome Project (Prof Axel Ullrich's lab): set up and screened for potential tyrosine kinase inhibitors of fibroblast growth factor receptor 4 (FGFR4).
-
ResearcherTemasek Life Sciences Laboratory, Singapore Feb 2006 - Feb 2008Singapore*Development and production of monoclonal antibodies specific for Campylobacter jejuni and Campylobacter coli - results were translated into commercial antibodies for C. jejuni and C. coli detection.*Creation and screening of potential live attenuated vaccine of Salmonella Enteritidis.
Dr. Ervinna Pang, Phd, Cva Education Details
-
Chartered Valuer And Appraiser (Cva)
-
Advanced Certificate In Sustainability And Sustainable Businesses -
Graduate Certificate In Directorship
-
Entrepreneurship Specialization Program -
Mba Foundation Series: Operations Management, Marketing, Financial Accounting, Corporate Finance
-
Medicine -
Biotechnology
Frequently Asked Questions about Dr. Ervinna Pang, Phd, Cva
What company does Dr. Ervinna Pang, Phd, Cva work for?
Dr. Ervinna Pang, Phd, Cva works for Nanyang Technological University Singapore
What is Dr. Ervinna Pang, Phd, Cva's role at the current company?
Dr. Ervinna Pang, Phd, Cva's current role is Adjunct Asst Prof.
What is Dr. Ervinna Pang, Phd, Cva's email address?
Dr. Ervinna Pang, Phd, Cva's email address is er****@****yer.com
What schools did Dr. Ervinna Pang, Phd, Cva attend?
Dr. Ervinna Pang, Phd, Cva attended International Max Planck Research School For Infectious Diseases And Immunology (Imprs-Idi), Nanyang Technological University & Institute Of Valuers And Appraisers Singapore, Singapore Management University, Singapore Management University & Singapore Institute Of Directors, University Of Pennsylvania - The Wharton School, University Of Pennsylvania - The Wharton School, University Of Sydney, Monash University.
Free Chrome Extension
Find emails, phones & company data instantly
Aero Online
Your AI prospecting assistant
Select data to include:
0 records × $0.02 per record
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial